atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Core Insights - atai Life Sciences announced the publication of Phase 1 results for BPL-003, a novel intranasal formulation of 5-MeO-DMT, indicating its safety and potential for treating mental health disorders [1][4] Group 1: Study Results - BPL-003 was evaluated in a double-blind, placebo-controlled Phase 1 study involving 44 healthy volunteers, demonstrating safety and tolerability with no serious adverse events reported [2] - The pharmacokinetics showed rapid absorption and elimination, with systemic exposure increasing dose-proportionally, and subjective psychedelic effects onset within minutes, resolving in less than two hours [2][3] - 60% of participants experienced a 'complete mystical experience' at doses of 10 mg and 12 mg, with 87% expressing willingness to accept the same or higher doses in the future [3] Group 2: Future Development - BPL-003 is currently under investigation in Phase 2a studies for Alcohol Use Disorder and Treatment Resistant Depression, with initial results from a Phase 2b study expected in H2 2024 [4] - The findings from Phase 1 could support a scalable treatment model that aligns with existing interventional treatment paradigms [2][4] Group 3: Company Background - Beckley Psytech is developing BPL-003, a short-duration psychedelic tryptamine associated with improvements in mood and anxiety, and is reported to produce mystical experiences comparable to high doses of psilocybin [5] - atai Life Sciences holds a 35.5% ownership stake in Beckley Psytech and has strategic plans for collaboration on digital therapeutics and market access activities [6]